IL272924B2 - Methods for making and using endoxifen - Google Patents

Methods for making and using endoxifen

Info

Publication number
IL272924B2
IL272924B2 IL272924A IL27292420A IL272924B2 IL 272924 B2 IL272924 B2 IL 272924B2 IL 272924 A IL272924 A IL 272924A IL 27292420 A IL27292420 A IL 27292420A IL 272924 B2 IL272924 B2 IL 272924B2
Authority
IL
Israel
Prior art keywords
oral formulation
endoxifen
cancer
iii
formula
Prior art date
Application number
IL272924A
Other languages
English (en)
Hebrew (he)
Other versions
IL272924A (en
IL272924B1 (en
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65635248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL272924(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of IL272924A publication Critical patent/IL272924A/en
Publication of IL272924B1 publication Critical patent/IL272924B1/en
Publication of IL272924B2 publication Critical patent/IL272924B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
  • Dental Preparations (AREA)
  • Primary Cells (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL272924A 2017-09-11 2018-09-10 Methods for making and using endoxifen IL272924B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556799P 2017-09-11 2017-09-11
US201762556884P 2017-09-11 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US201862693885P 2018-07-03 2018-07-03
PCT/US2018/050272 WO2019051416A1 (en) 2017-09-11 2018-09-10 METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Publications (3)

Publication Number Publication Date
IL272924A IL272924A (en) 2020-04-30
IL272924B1 IL272924B1 (en) 2023-09-01
IL272924B2 true IL272924B2 (en) 2024-01-01

Family

ID=65635248

Family Applications (3)

Application Number Title Priority Date Filing Date
IL304863A IL304863B2 (en) 2017-09-11 2018-09-10 Methods for making and using endoxifen
IL319158A IL319158A (en) 2017-09-11 2018-09-10 Methods for preparing and using endoxifen
IL272924A IL272924B2 (en) 2017-09-11 2018-09-10 Methods for making and using endoxifen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL304863A IL304863B2 (en) 2017-09-11 2018-09-10 Methods for making and using endoxifen
IL319158A IL319158A (en) 2017-09-11 2018-09-10 Methods for preparing and using endoxifen

Country Status (12)

Country Link
US (8) US11261151B2 (OSRAM)
EP (1) EP3681491A4 (OSRAM)
JP (3) JP7766316B2 (OSRAM)
KR (2) KR20200052349A (OSRAM)
CN (2) CN116832020A (OSRAM)
AU (3) AU2018329202B2 (OSRAM)
CA (1) CA3073836A1 (OSRAM)
IL (3) IL304863B2 (OSRAM)
MX (1) MX2020002649A (OSRAM)
SG (1) SG11202002105WA (OSRAM)
TW (2) TWI793165B (OSRAM)
WO (1) WO2019051416A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
KR20220042352A (ko) * 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用
KR20240146667A (ko) * 2022-01-12 2024-10-08 아토사 테라퓨틱스, 인크. (z)-엔독시펜의 조성물 및 그의 농축 방법
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use
WO2025019775A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Endoxifen compositions and methods of use thereof and synthesis thereof
WO2025137145A1 (en) 2023-12-18 2025-06-26 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
WO2025151443A1 (en) 2024-01-08 2025-07-17 Atossa Therapeutics, Inc. Endoxifen for treatment of rare cancers
WO2025207636A1 (en) 2024-03-25 2025-10-02 Atossa Therapeutics, Inc. Endoxifen for treating duchenne muscular dystrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
EP0168175B1 (en) 1984-06-12 1987-11-19 National Research Development Corporation Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
ZA200403281B (en) 2001-11-07 2005-12-13 Synthon Bv Tamsulosin tablets.
PT1572178E (pt) 2002-12-18 2006-09-29 Besins Int Lab Tratamento de mastalgia com 4-hidroxi-tamoxifeno
JP4684655B2 (ja) 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
EP1941871B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US20070190019A1 (en) 2003-06-23 2007-08-16 Chunfeng Guo Compositions and methods for topical administration
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070951A1 (en) 2004-01-16 2005-08-04 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
WO2005089511A2 (en) 2004-03-19 2005-09-29 Transform Pharmaceuticals, Inc. Novel pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20070059288A1 (en) 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CN101253160A (zh) 2005-07-06 2008-08-27 西科尔公司 制备来曲唑的改进方法
EP1909772A4 (en) 2005-08-05 2011-07-13 Nuvo Res Inc TRANSDERMAL DRUG FORMULATION
CN101287454B (zh) 2005-10-12 2011-07-20 兴和株式会社 乳腺癌和/或乳腺炎治疗用离子电渗疗法制剂
US20090208944A1 (en) 2005-12-09 2009-08-20 Goetz Matthew P Assessing outcomes for breast cancer patients treated with tamoxifen
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
WO2007141799A1 (en) 2006-06-05 2007-12-13 Cadila Healthcare Limited A process for preparing pure anastrozole
EA200970348A1 (ru) 2006-10-05 2009-10-30 Панацея Биотек Лтд. Новые инъецируемые депо-композиции и способ получения таких композиций
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
DK2101731T3 (en) 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
US20080207644A1 (en) 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2009032699A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100069781A1 (en) 2008-04-15 2010-03-18 Johansen Jerald A Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
MX2011000235A (es) 2008-07-08 2011-02-23 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EP2350111A1 (en) 2008-10-15 2011-08-03 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
EP3656376A1 (en) 2008-12-11 2020-05-27 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
CN103896786B (zh) * 2009-05-21 2015-11-25 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
WO2012125445A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
JP2014517843A (ja) 2011-05-24 2014-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬組成物用の圧縮コア
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
WO2013134230A1 (en) 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150321983A1 (en) 2012-10-19 2015-11-12 Fermion Oy A process for the preparation of ospemifene
HK1215256A1 (zh) 2012-11-20 2016-08-19 Vertex Pharmaceuticals Incorporated 用作吲哚胺2，3-二氧化酶的抑制劑的化合物
KR102363191B1 (ko) 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
IN2013MU00646A (OSRAM) 2013-03-04 2015-06-26 Intas Pharmaceuticals Ltd
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
US10174381B2 (en) 2013-10-18 2019-01-08 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015106094A1 (en) 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
MX2016011567A (es) 2014-03-11 2016-12-07 Repros Therapeutics Inc Sintesis de clomifeno usando un solvente unico.
CN107076747B (zh) 2014-06-04 2021-02-02 阿托萨治疗学公司 分子乳房摄影术
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
US20180200206A1 (en) 2015-07-14 2018-07-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
CN111212635A (zh) 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
AU2018329182A1 (en) 2017-09-11 2020-03-19 Atossa Therapeutics, Inc. Topical compositions and methods for treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOETZ ET AL.,, FIRST-IN-HUMAN PHASE I STUDY OF THE TAMOXIFEN METABOLITE Z-ENDOXIFEN IN WOMEN WITH ENDOCRINE-REFRACTORY METASTATIC BREAST CANCER, 30 August 2017 (2017-08-30) *
HENDERSON ET AL.,, PROFOUND REDUCTION IN TAMOXIFEN ACTIVE METABOLITE ENDOXIFEN IN A BREAST CANCER PATIENT TREATED WITH RIFAMPIN PRIOR TO INITIATION OF AN ANTI-TNFA BIOLOGIC FOR ULCERATIVE COLITIS: A CASE REPORT, 11 May 2016 (2016-05-11) *

Also Published As

Publication number Publication date
TWI793165B (zh) 2023-02-21
WO2019051416A1 (en) 2019-03-14
AU2024278243A1 (en) 2025-01-02
JP7766316B2 (ja) 2025-11-10
CA3073836A1 (en) 2019-03-14
US11572334B2 (en) 2023-02-07
TW201919596A (zh) 2019-06-01
US12479790B2 (en) 2025-11-25
KR20240155974A (ko) 2024-10-29
TWI878810B (zh) 2025-04-01
JP2025061858A (ja) 2025-04-11
TW202428251A (zh) 2024-07-16
IL319158A (en) 2025-04-01
IL272924A (en) 2020-04-30
EP3681491A1 (en) 2020-07-22
US12071391B2 (en) 2024-08-27
US20200207704A1 (en) 2020-07-02
US20240327333A1 (en) 2024-10-03
IL272924B1 (en) 2023-09-01
US20230365490A1 (en) 2023-11-16
JP2023126540A (ja) 2023-09-07
CN111328280A (zh) 2020-06-23
AU2023200013B2 (en) 2024-09-12
US20250282710A1 (en) 2025-09-11
US12275684B2 (en) 2025-04-15
US20220242816A1 (en) 2022-08-04
US20240425443A1 (en) 2024-12-26
US20230183166A1 (en) 2023-06-15
IL304863B2 (en) 2025-08-01
AU2018329202A1 (en) 2020-03-19
US11261151B2 (en) 2022-03-01
US20250223256A1 (en) 2025-07-10
IL304863B1 (en) 2025-04-01
US12281056B2 (en) 2025-04-22
CN116832020A (zh) 2023-10-03
KR20200052349A (ko) 2020-05-14
MX2020002649A (es) 2020-09-25
IL304863A (en) 2023-10-01
EP3681491A4 (en) 2021-06-30
SG11202002105WA (en) 2020-04-29
AU2018329202B2 (en) 2022-10-27
US11680036B1 (en) 2023-06-20
AU2023200013A1 (en) 2023-02-09
JP2020533283A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
IL272924B2 (en) Methods for making and using endoxifen
ES2727648T3 (es) Composiciones de goma de mascar que comprenden cannabinoides
ES2429159T3 (es) (S)-N-metilnaltrexona, proceso para su síntesis y su uso farmacéutico
TW202010502A (zh) 包含糖皮質激素受體拮抗劑之固體形式與調配物及其用途
CN101820916A (zh) 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
EP3405189A1 (en) Methods for treating cancer
PT1369115E (pt) Métodos para prevenir o cancro da mama pela administração de raloxifeno
CN104860907A (zh) 呋喃基化合物及其用途
CA3203125A1 (en) Endoxifen for treatment of ovarian cancer
JP2024541900A (ja) がんの治療のためのエンドキシフェン
US7358245B2 (en) Treatment of gastroesophageal reflux disease
CN119074753B (zh) 木犀草苷增敏顺铂在制备食管鳞癌治疗药物中的应用
US10736877B2 (en) Tryptamine-based ship inhibitors for the treatment of cancer
ES2457718B1 (es) Composición farmacéutica bucodispersable de melatonina
US10919906B2 (en) Conformationally-constrained bioisosteres of caffeic acid, and synthesis and therapeutic uses
JPH1112171A (ja) 消化器疾患治療薬
TW202203900A (zh) 用於治療癌症、子宮內膜異位症以及癌症或子宮內膜異位症患者的疼痛之二異丙胺化合物以及碘
BR112021006898A2 (pt) nova solução de combinação para tratar câncer refratário à quimioterapia
JP2005325081A (ja) 経口腸溶性製剤
WO2009007762A1 (en) Metronidazole containing extended release floating pharmaceutical composition
CN108653292A (zh) 一种化合物在治疗或预防高原病中的用途
ES2991518T3 (es) Composición para la mejora de la sensibilidad a la radiación que contiene aripiprazol como ingrediente activo
CN119074717A (zh) 白杨素增敏顺铂在治疗食管鳞癌中的应用
WO2023070071A2 (en) Small molecule activators of the immune system
BRPI0614949A2 (pt) preparação de liberação sustentada